Edit |   |
---|---|
Antigenic Specificity | CD140a, Human (Olaratumab biosimilar) |
Clone | Olaratumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG1 kappa |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | IF, IP, Neut, FuncS, ELISA, FCM |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human CD140a Recombinant Antibody (Olaratumab). Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha. It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses"). |
Immunogen | n/a |
Other Names | Anti-CD140a Recombinant Antibody, Research Grade Olaratumab, Anti-Human CD140a Recombinant Antibody(Olaratumab), 3G3, IMC-3G3, LY3012207, Antibody Drug Analogues, Monoclonal Antibody, YR1233, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 1024603-93-7 |
Catalog # | YR1233 |
Price | please inquire |
Order / More Info | CD140a, Human (Olaratumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |